度普利尤单抗注射液联合克立硼罗在成人中重度特应性皮炎中的临床研究

Clinical Study of Dupilumab Injection Combined with Crisaborole in Adults with Moderate to Severe Atopic Dermatitis

目的:探讨度普利尤单抗注射液联合克立硼罗在成人中重度特应性皮炎中的临床效果。方法:选取2021年5月—2022年5月江苏大学附属医院收治的102例成人中重度特应性皮炎患者,用随机数字表法分为常规组、观察组,各51例。常规组给予度普利尤单抗注射液,观察组给予度普利尤单抗注射液联合克立硼罗。对比两组临床疗效及治疗前后病情研究者整体评估(IGA)评分、湿疹面积及严重程度指数(EASI)评分、嗜酸性粒细胞(EOS)、免疫球蛋白E(IgE)变化情况,统计两组治疗期间不良反应发生情况。结果:观察组总有效率高于常规组(P<0.05)。治疗前,两组IGA、EASI评分对比差异均无统计学意义(P>0.05);两组治疗后IGA、EASI评分均低于治疗前(P<0.05),观察组IGA、EASI评分均更低(P<0.05)。治疗前,两组IgE、EOS水平对比差异均无统计学意义(P>0.05);两组治疗后IgE、EOS均较治疗前降低(P<0.05),观察组均更低(P<0.05)。常规组治疗期间出现1例局部红肿、1例结膜炎,观察组出现1例结膜炎、2例双手多个指间关节疼痛,两组不良反应总发生率对比差异无统计学意义(χ^(2)=0.210,P=0.647)。结论:度普利尤单抗注射液联合克立硼罗治疗成人中重度特应性皮炎可增强效果,减轻患者病情,降低IgE、EOS水平,且药物安全性良好。

Objective:To explore the clinical effect of Dupilumab Injection combined with Crisaborole in adults with moderate to severe atopic dermatitis.Method:A total of 102 adults with moderate to severe atopic dermatitis admitted to Affiliated Hospital of Jiangsu University from May 2021 to May 2022 were selected and divided into routine group and observation group by random number table method,with 51 cases in each group.The routine group was treated with Dupilumab Injection,while the observation group was treated with Dupilumab Injection combined with Crisaborole.The clinical efficacy and the changes of investigator global assessment(IGA)score,eczema area and severity index(EASI)score,eosinophils(EOS)and immunoglobulin E(IgE)before and after treatment were compared between the two groups,and the occurrence of adverse reactions in the two groups during treatment was analyzed.Result:The total effective rate of the observation group was higher than that of the routine group(P<0.05).Before treatment,there were no statistically significant differences in the IGA and EASI scores between the two groups(P>0.05);after treatment,the IGA and EASI scores of both groups were lower than those before treatment(P<0.05),while the IGA and EASI scores of the observation group were lower(P<0.05).Before treatment,there were no statistically significant differences in the levels of IgE and EOS between the two groups(P>0.05);after treatment,IgE and EOS in both groups decreased compared to before treatment(P<0.05),while in the observation group,they were both lower(P<0.05).During the treatment period,there was 1 case of local redness and swelling,1 case of conjunctivitis in the routine group,1 case of conjunctivitis and 2 cases of pain in multiple interphalangeal joints in both hands in the observation group,there was no statistically significant difference in the total incidence of adverse reactions between the two groups(χ^(2)=0.210,P=0.647).Conclusion:The combination of Dupilumab Injection and Crisaborole in the treatment of adult moderate to severe atopic dermatitis can enhance the therapeutic effect,alleviate the patient's condition,reduce IgE and EOS levels,and have good drug safety.